SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation ...
The US Food and Drug Administration (FDA) on Wednesday released final guidance for sponsors on when a standard release test and criteria may be used in lieu of extensive method development and ...
The U.S. Food and Drug Administration has announced a nationwide recall of thousands of bottles of a commonly prescribed blood pressure medication after testing revealed a potential problem that could ...
Pharmaceuticals are developed, designed, and commonly manufactured in laboratory settings. Laboratory testing is an essential need in almost every stage of pharmaceutical production and R&D, from the ...
When you take a time-release drug, you count on it doing what the package says: release the drug slowly into your bloodstream to provide benefits over the specified period of time. When the drug ...
The British Pharmacopoeia on Monday released its response to its consultation on dissolution testing and announced its plans to update its approach within its product monographs. The British ...
The Well News on MSN
FDA lists nationwide recall of over 11,000 bottles of blood pressure drug
WASHINGTON - More than 11,000 bottles of a prescription medication used to treat high blood pressure have been recalled ...
More than 11,000 bottles of blood pressure medication are being recalled over possibly failing dissolution specifications, ...
System addresses the pharmaceutical industry’s need for compliant, semi-automated testing of nanoparticle drug formulations. SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results